25th Process Development Symposium - conference papers

This item first appeared in 2007

Churchill College, Cambridge, 5-7 December 2007

The area of Process Development continues to be a challenging and important area for the research into and application of modern synthetic organic chemistry as well as enabling technologies.

The symposium aimed to bring together a wide range of speakers from across the pharmaceutical, agrochemical and fine chemical industries as well as from an academic background.

Wednesday 5 December
Chairman - Dr David Lathbury, AstraZeneca, UK
13:40   Diastereoselective Reductive Amination of 2,2,2- Trifl uoroacetophenones and a-Aminoesters (pdf 280Kb)
Dr Greg Hughes, Merck-Frosst, Canada
14:20   Process Aspects of Asymmetric Hydrogenation (pdf 680Kb)
Dr Ian Lennon, DowPharma, UK
15:00   Lab Automation within Roche Synthesis & Process Research and Kilolaboratory
Dr Jean-Michel Adam, F. Hoffman-La Roche Ltd., Switzerland
15:40   Tea
Process Chemistry Retrospectives
16:10   SK&F92334 - Chemical Development of the Original Blockbuster
Dr Mike Forth, GlaxoSmithKline, UK
16:40   Atenolol - 30 years of Life Cycle Management (pdf 2.2Mb)
Dr Stewart Jolly, AstraZeneca, UK
17:10   'A Blast from the Past' - Removal of Azide Protection in the Identification and Development of a Manufacturing Process to Amlodipine (pdf 80Kb)
Mr Alan Pettman, Pfizer Global Research & Development, UK
Thursday 6 December
Chairman- Dr Martin Jones, AstraZeneca, UK
09:00   MK-524 - A Study in Modern Chemical Development (pdf 1.3Mb)
Dr Edward Grabowski, Merck Research Laboratories (retired), USA
10:00   The Chemical Development of Tofi milast a PDE4 Inhibitor for Asthma and COPD (pdf 350 Kb)
Dr Lorraine Murtagh, Pfizer Global Research & Development, UK
10:40   Coffee
11:10   ZK-EPO, Chemical Development of a Totally Synthetic Epothilone Anti Cancer Drug
Dr Harribert Neh, Bayer Schering Pharma AG, Germany
11:50   Green Manufacture of Chiral Alcohols using Custom Evolved Biocatalysts - Replacing Boron Based Reducing Agents
Dr Jim Lalonde, Codexis Inc, USA
12:30   The Optimization and Scale-up Synthesis of BCL-2 Inhibitors
Dr David Hill, Abbott Laboratories, USA
Chairman - Dr John Carey, GlaxoSmithKline, UK

Large-Scale Application of Microreaction Technology within Commercial Chemical Production of DSM 
Dr Peter Poechlauer, DSM Pharmaceutical Products, Austria

14:50   The Synthesis of 9-Oxa-3,7-diazabicyclo[3.3.1]nonanes (Oxabispidines) and their use as Pharmaceutical Intermediates
Dr David Cladingboel, AstraZeneca, UK
16:00   Increasing Process Understanding through Data Analysis (pdf 500Kb)
Dr Alan Brown, Syngenta, UK
16:40   Process Research over 25 Years: A Personal Perspective (pdf 4.5Mb)
Professor Steven Ley, University of Cambridge, UK
Friday 7 December
Chairman - Dr Graham McDougald, Syngenta, UK
09:00   Process Development of Brivanib Alaninate, a VEGRF/FGFR Inhibitor
Dr Paul Lobben, Bristol-Myers Squibb, USA
09:40   Directed Evolution of Enzymes: New Biocatalysts for Organic Synthesis
Professor Nick Turner, University of Manchester Winner of GlaxoSmithKline, AstraZeneca and Pfizer Prize for Process Chemistry Research 2007
11:10   Redesigning and Developing the Synthetic Route to 435466
Dr David Catterick, GlaxoSmithKline, UK
11:50   Green Chemistry in the Pharmaceutical Industry
Dr Andy Wells, AstraZeneca, UK


Related Links

Show me news from
All themes
All categories
All years
search by